Compare Danaher Corporation (DHR) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs VanEck Rare Earth/Strategic Metals — how do they compare? Danaher Corporation trades at $201.01 (market cap $140.88B), while VanEck Rare Earth/Strategic Metals trades at $75.54. The key difference: Danaher Corporation pays a 0.8% dividend while VanEck Rare Earth/Strategic Metals pays none. Which is the better fit depends on your goals.
| DHR | REMX | |
|---|---|---|
Market Cap | $140.88B | — |
Sector | Health | Sector/Thematic |
52-Week High | $242.05 | $109.53 |
52-Week Low | $161.91 | $47.49 |
Enterprise Value | $153.66B | — |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $199.05, down 0.55% today, with a bullish technical outlook supported by moving averages and a consensus price target of $211.33. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.06 exceeding expectations. Revenue for 2025 was $24.57 billion, with a net income margin of 14.89%, though margins have declined from 2022 levels. Recent news includes the acquisition of Masimo and strong biotechnology segment performance.
The stock presents a favorable risk-reward profile with analyst support (69% buy ratings) and solid cash flow generation, but faces risks from margin compression and a high P/E ratio of 38.58. Upside is driven by earnings beats and strategic acquisitions, while headwinds include competitive pressures and macroeconomic uncertainty. The current price near $199 offers modest upside to the consensus target, with key resistance at $200.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $76.27, down 4.38% today amid bearish technical signals. The ETF faces high volatility (~50% annualized) and significant China concentration risk, though recent news highlights growing institutional interest in rare earths as critical for AI and defense infrastructure. Technical indicators show oversold RSI readings but dominant bearish moving average signals.
Outlook remains speculative given geopolitical supply chain dependencies and commodity price sensitivity. Investment appeal hinges on long-term rare earth demand growth from technology and energy transitions, but risks include China export controls and ETF liquidity constraints. Current levels near support at $76 may attract tactical buyers despite near-term bearish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
